Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 8322 results
Found 8322 results.


Johnson DH, Venuto C, Ritchie MD, et al. "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2014;24(4):195-203.
Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. "Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection." J. Acquir. Immune Defic. Syndr.. 2011;58(1):1-8.
Crump JA, Wu X, Kendall MA, et al. "Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study." BMC Infect. Dis.. 2015;15:12.
Paredes R, Lalama CM, Ribaudo HJ, et al. "Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure." J. Infect. Dis.. 2010;201(5):662-71.
Gross R, Tierney C, Andrade A, et al. "Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial." Arch. Intern. Med.. 2009;169(13):1224-32.
Robertson KR, Smurzynski M, Parsons TD, et al. "The prevalence and incidence of neurocognitive impairment in the HAART era." AIDS. 2007;21(14):1915-21.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
Dubé MP, Wu JW, Aberg JA, et al. "Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148." Antivir. Ther. (Lond.). 2006;11(8):1081-9.
Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. "Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants." AIDS Patient Care STDS. 2015;29(3):111-6.
Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. "Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study." Clin. Infect. Dis.. 2012;55(5):631-8.
Taiwo BO, Chan ES, Fichtenbaum CJ, et al. "Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study." Clin. Infect. Dis.. 2015;61(7):1179-88.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Tebas P, Zhang J, Yarasheski K, et al. "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)." J. Acquir. Immune Defic. Syndr.. 2007;45(2):193-200.
Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.
Lederman MM, Smeaton L, Smith KY, et al. "Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138." J. Infect. Dis.. 2006;194(12):1677-85.
Asmelash A, Zheng Y, Kaloustian KWools, et al. "Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa." BMC Infect. Dis.. 2014;14:331.
Meier A, J Chang J, Chan ES, et al. "Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1." Nat. Med.. 2009;15(8):955-9.
Lockman S, Hughes M, Sawe F, et al. "Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial." PLoS Med.. 2012;9(6):e1001236.
Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. "Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108." AIDS. 2006;20(5):725-9.
Fife KH, Wu JW, Squires KE, D Watts H, Andersen JW, Brown DR. "Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2009;51(3):274-82.
Zhao Y, Navia BA, Marra CM, et al. "Memantine for AIDS dementia complex: open-label report of ACTG 301." HIV Clin Trials. 2010;11(1):59-67.
Daar ES, Tierney C, Fischl MA, et al. "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1." Ann. Intern. Med.. 2011;154(7):445-56.
Okusanya O, Forrest A, DiFrancesco R, et al. "Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks." Antimicrob. Agents Chemother.. 2007;51(5):1822-6.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.
Thio CL, Smeaton L, Hollabaugh K, et al. "Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks." AIDS. 2015;29(10):1173-82.
Zheng Y, Hughes MD, Lockman S, et al. "Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens." Clin. Infect. Dis.. 2014;59(6):888-96.
Sattler FR, Rajicic N, Mulligan K, et al. "Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial." Am. J. Clin. Nutr.. 2008;88(5):1313-21.